ConductScience.org, home

Disease · MONDO_0001098

separation anxiety disorder

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. separation anxiety disorder. Diseases, record MONDO_0001098. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001098

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
separation anxiety disorder
Open Targets
Open Targets ID
MONDO_0001098
Open Targets
Other names
Adult-Onset Separation Anxiety Disorder, Children's separation anxiety, Pediatric-Onset Separation Anxiety Disorder, SAD, adult separation anxiety, adult separation anxiety disorder, childhood separation anxiety, childhood separation anxiety disorder, separation anxiety, separation anxiety in childhood
Open Targets
Disease Ontology
DOID:10685
Disease Ontology
MeSH
D001010
MeSH
NCI Thesaurus
C35014
NCI Thesaurus
Highest stage of its drugs
Phase 3, for 4 of its 5 drugs, from ClinicalTrials.gov
Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ESCITALOPRAMCHEMBL1508Small moleculePhase 3ClinicalTrials.gov222Drugs and targets
SERTRALINECHEMBL809Small moleculePhase 3ClinicalTrials.gov222Drugs and targets
FLUOXETINECHEMBL41Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
FLUVOXAMINECHEMBL814Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
GUANFACINE HYDROCHLORIDECHEMBL1200494Small moleculePhase 2ClinicalTrials.gov111Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
SLC6A4Sodium-dependent serotonin transporter4Serotonin transporter inhibitorPhase 3https://conductscience.org/library/genes/6532Drugs and targets
ADRA2AAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 2https://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 2https://conductscience.org/library/genes/151Drugs and targets
ADRA2CAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistPhase 2https://conductscience.org/library/genes/152Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00052078Child and Adolescent Anxiety Disorders (CAMS)Phase 34882017-04-25Anxiety Disorders, Social Phobia, Generalized Anxiety DisorderSERTRALINEIts record names the diseaseClinicalTrials.gov
NCT01470469SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)Phase 2832014-05-23Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, SocialGUANFACINE HYDROCHLORIDEIts record names the diseaseClinicalTrials.gov
NCT04598230Partners in Caring for Anxious YouthPhase 3468Anxiety, Separation, Anxiety, Generalized, Anxiety, SocialESCITALOPRAM, FLUOXETINE, SERTRALINEIts record names the diseaseClinicalTrials.gov
NCT01293838Cipralex® for Anxiety Disorders in AdolescentsPhase 130Anxiety DisorderESCITALOPRAMIts record names the diseaseClinicalTrials.gov
NCT00000389Treatment for Anxiety in ChildrenPhase 3Obsessive-Compulsive Disorder, Anxiety Disorders, Generalized Anxiety Disorder, Social Phobia, Separation AnxietyFLUVOXAMINEIts record names the diseaseClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrial
SPD503 vs PLACEBO: serious adverse events0 of 620 of 2183NCT01470469

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
28384010RESULT1PubMed
25721183RESULT2PubMed
25486372RESULT1PubMed
24565357RESULT2PubMed
24417601RESULT1PubMed
22122292RESULT1PubMed
20206470RESULT1PubMed
20051130RESULT1PubMed
18974308RESULT2PubMed
41773906DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001098

GET https://conductscience.org/api/diseases/v1/MONDO_0001098/papers?page=2